Finding diverse hit candidates through phenotype-guided Virtual Screening using Artificial Intelligence on molecular and morphology data

Format:

Joint collaboration with Jagiellonian University

About the poster

This poster, prepared for OBayConnect 2024, presents a comparative analysis of multiple AI strategies designed to integrate chemical structure data with high-content phenotypic profiles for compound similarity matching. The goal of the project is to improve our ability to identify and group compounds based on shared biological activity by leveraging complementary data modalities.

In this study, several models—such as SimSiam, SPOCO, and anchoring methods combining ECFP or R-MAT with Cell Painting (CP) features—are evaluated using metrics like recall@10, recall@100, and median ranking position. These metrics help assess how effectively the models retrieve compounds with similar biological effects from large datasets. The results highlight the trade-offs between data types and architectures, showcasing the potential of AI-driven fusion models to accelerate drug discovery through more nuanced and biologically meaningful compound matching.

This work underscores the importance of robust benchmarking in AI-for-drug-discovery applications and provides practical insights into how combining structure-based and image-based data can refine virtual screening and repurposing pipelines.

You might be also interested in:

Can AI Stop the Cost Spiral in Drug Discovery? Summary of Our Expert Talk at BioTech X 2025
Your monthly AI in biotech digest – October
Abstract visualization of AI-driven analysis of patient data, representing precision medicine and responder identification.
Precision Trials: Using AI to Identify Responders
Poster: Safer pHLA-Targeted Immunotherapies Through AI and Computational Immunology

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!